Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who
received antipsychotic medications. Increasing evidence suggests that TD may result from
antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether
cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we
conducted a 30-week randomized, double-blind, placebo-controlled crossover study of
galantamine in 36 patients with TD.